|
1. Sinatra ST, Roberts JC. Enhancing
cardiac energy with ribose. Life Extension. 2007
May;13(50):26-31.
2. Gao L, Laude K, Cai H.
Mitochondrial Pathophysiology, Reactive Oxygen Species,
and Cardiovascular Diseases. Vet Clin North Am Small
Anim Pract. 2008 Jan;38(1):137-55.
3. Kumar D, Lou H, Singal PK.
Oxidative stress and apoptosis in
heart dysfunction.
Herz. 2002 Nov;27(7):662-8.
4. Sorescu D, Griendling KK. Reactive
oxygen species, mitochondria, and NAD(P)H oxidases in
the development and progression of
heart failure.
Congest Heart Fail.
2002 May;8(3):132-40.
5. Gustafsson AB, Gottlieb RA.
Heart mitochondria:
gates of life and death. Cardiovasc. 2008 Feb
1;77(2):334-43.
6. Zimmer HG, Ibel H. Ribose
accelerates the repletion of the ATP pool during
recovery from reversible ischemia of the rat myocardium.
J Mol Cell Cardiol. 1984 Sep;16(9):863-6.
7. St Cyr JA, Bianco RW, Schneider
JR, et al. Enhanced high energy phosphate recovery with
ribose infusion after global myocardial ischemia in a
canine model. J Surg Res. 1989 Feb;46(2):157-62.
8. Ward HB, Wang T, Einzig S, Bianco
RW, Foker JE. Prevention of ATP catabolism during
myocardial ischemia: a preliminary report. J Surg Res.
1983 Apr;34(4):292-7.
9. Wyatt DA, Ely SW, Lasley RD, et
al. Purine-enriched asanguineous cardioplegia retards
adenosine triphosphate degradation during ischemia and
improves postischemic ventricular function. J Thorac
Cardiovasc Surg. 1989 May;97(5):771-8.
10. Smolenski RT, Raisky O, Slominska
EM, et al. Protection from reperfusion injury after
cardiac transplantation by inhibition of adenosine
metabolism and nucleotide precursor supply. Circulation.
2001 Sep 18;104(12 Suppl 1):I246-52.
11. Zimmer HG, Martius PA, Marschner
G. Myocardial infarction in rats: effects of metabolic
and pharmacologic interventions. Basic Res Cardiol. 1989
May;84(3):332-43.
12. Thirunavukkarasu M, Penumathsa S,
Juhasz B, et al. Enhanced cardiovascular function and
energy level by a novel chromium (III)-supplement.
Biofactors. 2006;27(1-4):53-67.
13. Thirunavukkarasu M, Penumathsa
SV, Juhasz B, et al. Niacin-bound chromium enhances
myocardial protection from ischemia-reperfusion injury.
Am J Physiol Heart
Circ Physiol. 2006 Aug;291(2):H820-6.
14. Pauly DF, Pepine CJ. Ischemic
heart disease:
metabolic approaches to management. Clin Cardiol. 2004
Aug;27(8):439-41.
15. Pauly DF, Johnson C, St Cyr JA.
The benefits of ribose in cardiovascular disease. Med
Hypotheses. 2003 Feb;60(2):149-51.
16. Hegewald MG, Palac RT, Angello
DA, Perlmutter NS, Wilson RA. Ribose infusion
accelerates thallium redistribution with early imaging
compared with late 24-hour imaging without ribose. J Am
Coll Cardiol. 1991 Dec;18(7):1671-81.
17. Perlmutter NS, Wilson RA, Angello
DA, et al. Ribose facilitates thallium-201
redistribution in patients with coronary artery disease.
J Nucl Med. 1991 Feb;32(2):193-200.
18. Wallen WJ, Belanger MP, Wittnich
C. Preischemic administration of ribose to delay the
onset of irreversible ischemic injury and improve
function: studies in normal and hypertrophied
hearts. Can J
Physiol Pharmacol. 2003 Jan;81(1):40-7.
19. Omran H, Illien S, MacCarter D,
St CJ, Luderitz B. D-Ribose improves diastolic function
and quality of life in congestive
heart failure
patients: a prospective feasibility study. Eur J
Heart Fail. 2003
Oct;5(5):615-9.
20. Pliml W, von AT, Stablein A, et
al. Effects of ribose on exercise-induced ischaemia in
stable coronary artery disease. Lancet. 1992 Aug
29;340(8818):507-10.
21. Choo J, Burke LE, Pyo HK.
Improved quality of life with cardiac rehabilitation for
post-myocardial infarction patients in Korea. Eur J
Cardiovasc Nurs. 2007 Sep;6(3):166-71.
22. Ades PA. Individualized
preventive care in cardiac rehabilitation: adapted from
AACVPR Award of Excellence Lecture, Charleston, WVa,
October, 2006. J Cardiopulm Rehabil Prev. 2007
May;27(3):130-4.
23. Moore SM, Dolansky MA, Ruland CM,
Pashkow FJ, Blackburn GG. Predictors of women’s exercise
maintenance after cardiac rehabilitation. J Cardiopulm
Rehabil. 2003 Jan;23(1):40-9.
24. Annesi J. Relations of
self-motivation, perceived physical condition, and
exercise-induced changes in revitalization and
exhaustion with attendance in women initiating a
moderate cardiovascular exercise regimen. Women Health.
2005;42(3):77-93.
25. Hellsten-Westing Y, Norman B,
Balsom PD, Sjodin B. Decreased resting levels of adenine
nucleotides in human skeletal muscle after
high-intensity training. J Appl Physiol. 1993
May;74(5):2523-8.
26. Stathis CG, Febbraio MA, Carey
MF, Snow RJ. Influence of sprint training on human
skeletal muscle purine nucleotide metabolism. J Appl
Physiol. 1994 Apr;76(4):1802-9.
27. Hellsten Y, Richter EA, Kiens B,
Bangsbo J. AMP deamination and purine exchange in human
skeletal muscle during and after intense exercise. J
Physiol. 1999 Nov 1;520 Pt 3:909-20.
28. Tullson PC, John-Alder HB, Hood
DA, Terjung RL. De novo synthesis of adenine nucleotides
in different skeletal muscle fiber types. Am J Physiol.
1988 Sep;255(3 Pt 1):C271-7.
29. Zarzeczny R, Brault JJ, Abraham
KA, Hancock CR, Terjung RL. Influence of ribose on
adenine salvage after intense muscle contractions. J
Appl Physiol. 2001 Oct;91(4):1775-81.
30. Tullson PC, Terjung RL. Adenine
nucleotide synthesis in exercising and endurance-trained
skeletal muscle. Am.J Physiol. 1991 Aug;261(2 Pt
1):C342-7.
31. Brault JJ, Terjung RL. Purine
salvage to adenine nucleotides in different skeletal
muscle fiber types. J Appl Physiol. 2001
Jul;91(1):231-8.
32. Hellsten Y, Skadhauge L, Bangsbo
J. Effect of ribose supplementation on resynthesis of
adenine nucleotides after intense intermittent training
in humans. Am J Physiol Regul Integr Comp Physiol. 2004
Jan;286(1):R182-8.
33. Berardi JM, Ziegenfuss TN.
Effects of ribose supplementation on repeated sprint
performance in men. J Strength Cond Res. 2003
Feb;17(1):47-52.
34. Dunne L, Worley S, Macknin M.
Ribose versus dextrose supplementation, association with
rowing performance: a double-blind study. Clin J Sport
Med. 2006 Jan;16(1):68-71.
35. Kerksick C, Rasmussen C, Bowden
R, et al. Effects of ribose supplementation prior to and
during intense exercise on anaerobic capacity and
metabolic markers. Int J Sport Nutr Exerc Metab. 2005
Dec;15(6):653-64.
36. Op ‘t EB, Van LM, Brouns F, et
al. No effects of oral ribose supplementation on
repeated maximal exercise and de novo ATP resynthesis. J
Appl Physiol. 2001 Nov;91(5):2275-81.
37. Peveler WW, Bishop PA, Whitehorn
EJ. Effects of ribose as an ergogenic aid. J Strength
Cond Res. 2006 Aug;20(3):519-22.
38. Segal S, Foley J, Wyngaarden JB.
Hypoglycemic effect of D-ribose in man. Proc Soc Exp
Biol Med. 1957 Jul;95(3):551-5.
39. Gross M, Reiter S, Zollner N.
Metabolism of D-ribose administered continuously to
healthy persons and to patients with myoadenylate
deaminase deficiency. Klin Wochenschr. 1989 Dec
4;67(23):1205-13.
40. Dimroth P, von BC, Meier T.
Catalytic and mechanical cycles in F-ATP synthases.
Fourth in the Cycles Review Series. EMBO Rep. 2006
Mar;7(3):276-82.
41. Jain M, Cui L, Brenner DA, et al.
Increased myocardial dysfunction after
ischemia-reperfusion in mice lacking glucose-6-phosphate
dehydrogenase. Circulation. 2004 Feb 24;109(7):898-903.
42. Pacher P, Szabo C. Role of
poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular
diseases: the therapeutic potential of PARP inhibitors.
Cardiovasc Drug Rev. 2007;25(3):235-60.
43. Zimmer HG. The oxidative pentose
phosphate pathway in the
heart: regulation, physiological significance,
and clinical implications. Basic Res Cardiol. 1992
Jul;87(4):303-16.
44. Zimmer HG. Regulation of and
intervention into the oxidative pentose phosphate
pathway and adenine nucleotide metabolism in the
heart. Mol Cell
Biochem. 1996 Jul;160-161:101-9.
45. Clay MA, Stewart-Richardson P,
Tasset DM, Williams JF. Chronic alcoholic cardiomyopathy.
Protection of the isolated ischaemic working
heart by ribose.
Biochem Int. 1988 Nov;17(5):791-800.
46. Parang P, Singh B, Arora R.
Metabolic modulators for chronic cardiac ischemia. J
Cardiovasc Pharmacol Ther. 2005 Dec;10(4):217-23.
47. Pauly DF, Pepine CJ. D-Ribose as
a supplement for cardiac energy metabolism. J Cardiovasc
Pharmacol Ther. 2000 Oct;5(4):249-58.
48. Kendler BS. Supplemental
conditionally essential nutrients in cardiovascular
disease therapy. J Cardiovasc Nurs. 2006 Jan;21(1):9-16.
49. Lamberts RR, Caldenhoven E,
Lansink M, et al. Preservation of diastolic function in
monocrotaline-induced right ventricular hypertrophy in
rats. Am J Physiol Heart
Circ Physiol. 2007;293:H1869-H1876.
50. Teitelbaum JE, Johnson C, St CJ.
The use of D-ribose in chronic fatigue syndrome and
fibromyalgia: a pilot study. J Altern Complement Med.
2006;12:857-62.
|